78302-26-8

Basic information

• Product Name: Loxacor-d4
• Synonyms: 2-[1-(2,6-Dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole-d4;Ba-168-d4;Britlofex-d4;Lofetensin-d4;Lofexidine-d4;Loxacor-d4;MDL-14042A-d4;Lofexidine-d4 Hydrochloride
• CAS NO: 78302-26-8
• Molecular Formula: C₁₁H₁₂Cl₂N₂O
• Molecular Weight: 0
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Isotope Labelled Compounds
• Mol File: 78302-26-8.mol

Chemical Properties

• Melting Point: 229-231?C
• Boiling Point: 421.517°C at 760 mmHg
• Flash Point: 208.726°C
• Appearance: /
• Density: 1.412g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: -20°C Freezer
• CAS DataBase Reference: Loxacor-d4(CAS DataBase Reference)
• NIST Chemistry Reference: Loxacor-d4(78302-26-8)
• EPA Substance Registry System: Loxacor-d4(78302-26-8)

Safety Data

• Hazardous Substances Data: 78302-26-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Loxacor-d4 is used as a research compound for studying the pharmacological effects and mechanisms of action of Lofexidine. Its deuterated nature allows for enhanced stability and reduced metabolism, making it an ideal candidate for investigating the role of a2-Adrenoceptor agonists in various physiological and pathological processes.
Used in Treatment of Opioid Withdrawal Symptoms:
Loxacor-d4 is used as a therapeutic agent for the treatment of opioid withdrawal symptoms. Its a2-Adrenoceptor agonist activity helps alleviate the symptoms associated with opioid withdrawal, such as anxiety, agitation, and insomnia, providing a safer and more effective treatment option for patients undergoing detoxification.
Used as an Antihypertensive Agent:
In addition to its use in opioid withdrawal treatment, Loxacor-d4 is also utilized as an antihypertensive agent. Its a2-Adrenoceptor agonist properties contribute to the reduction of blood pressure by causing vasodilation and decreasing cardiac output, making it a potential treatment option for individuals suffering from hypertension.

InChI:InChI=1/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)/i5D2,6D2

Upstream product

• 37164-19-5 ethylene-d4-diamine 
• 101934-13-8 C₁₁H₁₃Cl₂NO₂*ClH 

Downstream Products

• 1206845-57-9 (+/-)-[4,4,5,5-(2)H4]-2-(1-[2,6-dichlorophenoxy]ethyl)-Δ2-imidazoline hydrochloride 
• 1206845-55-7 C₂₀H₂₆⁽²⁾H₄Cl₂N₂O₃Si 
• 1206845-56-8 C₂₀H₂₆⁽²⁾H₄Cl₂N₂O₃Si 

Relevant articles and documents

Rac- and R-(+)-[4,4′,5,5′-2H4]-2- (1′-[2″,6″-dichlorophenoxy]-ethyl)-Δ2- imidazoline (lofexidine)

The synthesis of the d4-forms of rac- and R-lofexidine was accomplished. Two methods are described; one method is a two-step synthesis of rac-d4-lofexidine from 2-chloropropionitrile, the second method is a three-step preparation of R-d4-lofexidine in absolute enantiomeric purity from S-methyl lactate. The commercial availability of R-methyl lactate makes this latter enantioselective synthesis applicable also to the synthesis of S-d4- lofexidine. These procedures also conserve the utilization of the relatively expensive [1,1′,2,2′-2H 4]ethylene diamine precursor. The availability of S- and R-d 4-lofexidines will enable pharmacokinetic studies to be carried out to determine if differential in vivo metabolism of the two enantiomers of lofexidine occurs. Copyright